We are live on ! Find out more
NPCE icon

Neuropace
NPCE

41 hedge funds and large institutions have $156M invested in Neuropace in 2023 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,700% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 1

75% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 8

64% more funds holding

Funds holding: 25 → 41 (+16)

11% less capital invested

Capital invested by funds: $176M → $156M (-$19.7M)

12.24% less ownership

Funds ownership: 69.89% → 57.65% (-12%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
41
Holders Change
+16
Holders Change %
+64%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
18
Increased
14
Reduced
8
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$20.1M
2
KLC
Kent Lake Capital
Nevada
+$770K
3
Renaissance Technologies
Renaissance Technologies
New York
+$511K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$337K
5
Jane Street
Jane Street
New York
+$294K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.9M
2
EI
EAM Investors
California
-$602K
3
NCM
Nantahala Capital Management
Connecticut
-$369K
4
SCM
Soleus Capital Management
Connecticut
-$263K
5
BCM
Bridgeway Capital Management
Texas
-$209K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$50.7M +$20.1M +2,521,716 +105%
O
2
OrbiMed
New York
$41.3M -$66.3K -8,314 -0.2%
SCM
3
Soleus Capital Management
Connecticut
$25.1M -$263K -33,037 -1%
NCM
4
Nantahala Capital Management
Connecticut
$12.1M -$369K -46,238 -4%
KLC
5
Kent Lake Capital
Nevada
$6.92M +$770K +96,529 +17%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$4.83M -$1.9M -238,164 -34%
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.26M +$215K +27,021 +7%
Millennium Management
8
Millennium Management
New York
$1.78M -$93.8K -11,766 -6%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.2M +$46.2K +5,787 +5%
Renaissance Technologies
10
Renaissance Technologies
New York
$1.12M +$511K +64,040 +145%
BlackRock
11
BlackRock
New York
$892K +$212K +26,534 +44%
EI
12
EAM Investors
California
$682K -$602K -75,475 -53%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$436K +$337K +42,285 New
Jane Street
14
Jane Street
New York
$380K +$294K +36,822 New
Northern Trust
15
Northern Trust
Illinois
$361K +$102K +12,821 +58%
Citigroup
16
Citigroup
New York
$361K +$255K +32,037 +1,074%
BCM
17
Bridgeway Capital Management
Texas
$350K -$209K -26,148 -44%
State Street
18
State Street
Massachusetts
$344K +$797 +100 +0.3%
Bank of America
19
Bank of America
North Carolina
$329K +$211K +26,405 +480%
Balyasny Asset Management
20
Balyasny Asset Management
Illinois
$280K +$217K +27,156 New
Qube Research & Technologies (QRT)
21
Qube Research & Technologies (QRT)
United Kingdom
$270K +$190K +23,803 +992%
6CM
22
683 Capital Management
New York
$257K +$199K +24,933 New
Citadel Advisors
23
Citadel Advisors
Florida
$248K +$192K +24,055 New
LCM
24
Laurion Capital Management
New York
$213K +$165K +20,699 New
ECM
25
ExodusPoint Capital Management
New York
$204K +$158K +19,791 New
1
2

NPCE Hedge Fund Activity: Q4 2023 in Review

41 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q4 2023, worth a combined $156M — down 11% from $176M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new NPCE positions and 1 closed out — a net gain of 17 holders — while 14 added to existing stakes and 8 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $20.1M. The largest seller was Fidelity Investments, cutting an estimated $1.9M.

  • 41 institutional investors held Neuropace (NPCE) as of Q4 2023, up from 25 in Q3 2023.
  • Funds reported $156M of Neuropace stock for Q4 2023, down 11% quarter-over-quarter.
  • 18 funds opened new Neuropace positions in Q4 2023 and 1 closed out, a net change of +17 holders.
  • The largest Neuropace buyer in Q4 2023 was Morgan Stanley, an estimated $20.1M added.
  • The largest Neuropace seller in Q4 2023 was Fidelity Investments, an estimated $1.9M sold.

Based on aggregated 13F filings for Q4 2023.